22900-83-0

Basic information

• Product Name: ETHYL 2-BROMO-4-METHYL-1,3-THIAZOLE-5-CARBOXYLATE
• Synonyms: ETHYL 2-BROMO-4-METHYL-1,3-THIAZOLE-5-CARBOXYLATE;ETHYL 2-BROMO-4-METHYLTHIAZOLE-5-CARBOXYLATE;ETHYL 2-BROMO-4-METHYLTHIAZOLE-5-CARBOX&;Ethyl 2-bromop4-methyl-1,3-thiazole-5-carboxylate;2-bromo-4-methyl-thiazole-5-carboxylic acid ethyl ester;Ethyl 2-broMo-4-Methylthiazole-5-carboxylate;Ethyl 2-broMo-4-Methylthiazole-5-carboxylate 97%;2-Bromo-4-methyl-5-thiazolecarboxylic acid ethyl ester
• CAS NO: 22900-83-0
• Molecular Formula: C₇H₈BrNO₂S
• Molecular Weight: 250.11
• Product Categories: Thiazole series;Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Thiazoles;ThiazolesHeterocyclic Building Blocks;thiazole, carboxylate
• Mol File: 22900-83-0.mol
• Article Data: 16

Chemical Properties

• Melting Point: 65-69 °C(lit.)
• Boiling Point: 287.086 °C at 760 mmHg
• Flash Point: 127.426 °C
• Appearance: /
• Density: 1.573 g/cm³
• Vapor Pressure: 0.003mmHg at 25°C
• Refractive Index: 1.563
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: -0.10±0.10(Predicted)
• Water Solubility: Insoluble in water.
• CAS DataBase Reference: ETHYL 2-BROMO-4-METHYL-1,3-THIAZOLE-5-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-BROMO-4-METHYL-1,3-THIAZOLE-5-CARBOXYLATE(22900-83-0)
• EPA Substance Registry System: ETHYL 2-BROMO-4-METHYL-1,3-THIAZOLE-5-CARBOXYLATE(22900-83-0)

Safety Data

• Hazard Codes: Xi
• Statements: 37/38-41
• Safety Statements: 26-36
• RIDADR: 1759
• WGK Germany: 3
• HazardClass: IRRITANT
• PackingGroup: Ⅲ
• Hazardous Substances Data: 22900-83-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 2-bromo-4-methyl-1,3-thiazole-5-carboxylate is used as a key intermediate in the synthesis of various thiazole-4and -5-carboxylates. These compounds have potential applications in the development of new pharmaceuticals due to their diverse chemical properties and reactivity.
Used in Chemical Research:
Ethyl 2-bromo-4-methyl-1,3-thiazole-5-carboxylate is also utilized in chemical research, particularly in the study of rotational isomers of thiazole-4and -5-carboxylates. The research on these isomers can provide valuable insights into the structural and conformational aspects of these compounds, which can be useful for designing new molecules with specific properties and applications.
Used in Drug Discovery:
Ethyl 2-bromo-4-methyl-1,3-thiazole-5-carboxylate has been identified as a component in the discovery of thiazolylpyridinone SCD1 inhibitors. These inhibitors are designed to have preferential liver distribution, which can help in targeting liver-related diseases more effectively. Additionally, these inhibitors are aimed at reducing mechanism-based adverse effects, making them potentially safer and more effective therapeutic options.

InChI:InChI=1/C7H8BrNO2S/c1-3-11-6(10)5-4(2)9-7(8)12-5/h3H2,1-2H3

Upstream product

• 7210-76-6 ethyl-2-amino-4-methylthiazole-5-carboxylate 
• 110-46-3 isopentyl nitrite 
• 141-97-9 ethyl acetoacetate 
• 84911-18-2 ethyl 2-bromoacetoacetate 
• 609-15-4 ethyl 2-chloro-3-oxo-butyrate 

Downstream Products

• 78633-83-7 2-(p-Acetylaminobenzenesulfonamido)-4-methyl-5-carboethoxythiazole 
• 40003-41-6 2-bromo-4-methyl-thiazole-5-carboxylic acid 
• 40003-13-2 2-(4-chloro-3-methyl-phenoxy)-4-methyl-thiazole-5-carboxylic acid ethyl ester 
• 53040-04-3 2-(4-methoxycarbonylmethoxy-phenylsulfanyl)-4-methyl-thiazole-5-carboxylic acid ethyl ester 
• 58535-97-0 2-(4-methoxycarbonylmethoxy-3-methyl-phenylsulfanyl)-4-methyl-thiazole-5-carboxylic acid ethyl ester 
• 58535-99-2 2-[4-(2-methoxycarbonyl-ethoxy)-phenylsulfanyl]-4-methyl-thiazole-5-carboxylic acid ethyl ester 
• 58535-98-1 2-[4-(1-methoxycarbonyl-ethoxy)-phenylsulfanyl]-4-methyl-thiazole-5-carboxylic acid ethyl ester 
• 58536-01-9 2-[4-(3-methoxycarbonyl-propoxy)-phenylsulfanyl]-4-methyl-thiazole-5-carboxylic acid ethyl ester 
• 40003-24-5 4-methyl-2-(toluene-4-sulfonyl)-thiazole-5-carboxylic acid ethyl ester 
• 40003-26-7 2-(4-chloro-benzenesulfonyl)-4-methyl-thiazole-5-carboxylic acid ethyl ester 
• 40003-23-4 2-benzenesulfonyl-4-methyl-thiazole-5-carboxylic acid ethyl ester 
• 40003-25-6 2-(4-acetylamino-benzenesulfonyl)-4-methyl-thiazole-5-carboxylic acid ethyl ester 
• 58536-00-8 2-[4-(2-methoxycarbonyl-ethoxy)-3-methyl-phenylsulfanyl]-4-methyl-thiazole-5-carboxylic acid ethyl ester 
• 40003-15-4 ethyl 4-methyl-2-phenylsulfanylthiazole-5-carboxylate 

Relevant articles and documents

Green synthesis approaches of 2-bromo-4-methyl thiazole-5-carboxamide derivatives as potent microbial agents

As a part of our ongoing research in the development of new, selective and environmental friendly methodologies, herein we report a new series of 2-bromo-4-methylthiazole-5-carboxamide derivatives using polyethylene glycol-400 (PEG-400) as a solvent. All

Facile synthesis of novel (1-Aryl/alkyl-1H-1,2,3-triazol- 4-yl)methyl-2-bromo-4-methylthiazole-5-carboxylates by Cu(I) catalyzed click reaction

A number of novel thiazole-triazole heterocycles bearing (1-aryl/alkyl-1H-1,2,3-triazol-4-yl)methyl- 2-bromo-4-methylthiazole-5-carboxylates was synthesized through the click reaction. The structure of all new synthesized compounds was established by sup

Pyrazole-Thiazole Core-Containing Analogs Exhibit Adjunctive Activity with Meropenem against Carbapenem-Resistant Enterobacteriaceae (CRE)

Pyrazole-thiazole core-containing compound KP-40 and 20 novel derivatives were designed and synthesized through traditional SAR analysis. These molecules displayed adjunctive activity with meropenem against Gram-negative bacteria evidenced by a range of fractional inhibitory concentration (FIC=0.5–0.25) and minimum adjunctive concentration (MAC=128–32 μM) values. Of this series of molecules, four compounds displayed notable adjunctive potential, with FIC and MAC values of 0.25 and 32 μM, respectively. Moreover, the solubility of these compounds was improved to an acceptable range. Further analysis using our “in house” permeation and efflux multi parameter optimization (PEMPO) algorithm revealed key physicochemical properties that may be critical for the development of active Gram-negative antibacterials. Taking PEMPO scores into consideration prior to executing synthesis of analogs may be a simple, yet rapid and effective strategy that can be used in conjunction with traditional SAR approaches to aid in the design of potent Gram-negative antibacterials.

Synthesis and Fungicidal Activity of Novel 2-Heteroatomthiazole-based Carboxanilides

A new series of 2-heteroatomthiazole-based carboxanilides (8) are prepared by reacting 2-heteroatomthiazole-based carboxylic acid chlorides with 2,6-dibromo-4-(trifluoromethoxy)aniline. The structures of all the newly synthesized compounds were supported by spectroscopic data NMR, MS, and elemental analysis, etc. Bioassay showed that the compounds exhibited potent fungicidal activities against Rhizoctonia solani, etc. Particularly, N-(2,6-dibromo-4-(trifluoromethoxy)phenyl)-2-methoxy-4-(trifluoromethyl)thiazole-5-carboxamide (8a-2) showed fungicidal potency which was comparable to that of Thifluzamide, the only commercialized thiazole carboxanilide fungicides of succinate dehydrogenase inhibitor (SDHI).

NOVEL OXAZOLE AND THIAZOLE COMPOUNDS AS Β-CATENIN MODULATORS AND USES THEREOF

Heterocyclic compounds according to formula I: wherein A, B, Y, and Cy are as described herein, are provided as inhibitors of the Wnt pathway that specifically target the activity of the stabilized pool of B-cat. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, cancer, and other conditions related to Wnt pathway dysfunction, including various cancers and pulmonary fibrosis.

Design and synthesis of novel triazole derivatives containing γ-lactam as potential antifungal agents

A series of novel triazole derivatives containing γ-lactam were designed and synthesized, and their structures were confirmed by 1H NMR, 13C NMR and HRMS. The in vitro antifungal activities of the target compounds were evaluated. The results showed that all of the compounds exhibited stronger activity against the six clinically important fungi tested than fluconazole. 3D and 3E showed comparative activity against the fungi tested except for Candida glabrata and Aspergillus fumigatus as voriconazole. In addition, the docking model for 2A and CYP51 was investigated.

AMIDE COMPOUND

A compound represented by the formula (I) wherein ring Cy1 is a 5-membered aromatic heterocycle optionally further substituted besides a group represented by -A-B, ring Cy2 is an optionally substituted benzene ring, ring Cy3 is an optionally substituted 5-membered aromatic heterocycle, ring Cy4 is an optionally substituted 6-membered aromatic ring, A is -CONRa- or -NRaCO-, Ra is a hydrogen atom or a substituent, B is a hydrogen atom or an optionally substituted C1-6 alkyl-group, X is an optionally substituted C1-2 alkylene, -Y-, -Y-CH2- or - CH2-Y-, Y is an oxygen atom, -NRb- or -S(O)m-, Rb is a hydrogen atom or a substituent, and m is 0, 1 or 2, provided that N-methyl-4-[2-[3,4,5-trimethoxyphenyl)amino]-1,3-benzoxazol-7-yl]thiophene-2-carboxamide is excluded, or a salt thereof, has an agonistic action on GPR52, and is useful as an agent for the prophylaxis or treatment of schizophrenia and the like.

PROCESSES FOR THE PREPARATION OF FEBUXOSTAT AND SALTS THEREOF

There is provided a process for preparing febuxostat of formula (I) or a pharmaceutically acceptable salt thereof, the process comprising: condensing a compound of formula (A) with a compound of formula (B) to form an ester of febuxostat; hydrolyzing the ester of febuxostat to febuxostat, and optionally converting the febuxostat to a pharmaceutically acceptable salt thereof, wherein: R' is an activating group selected from boronic acid or lithium; R is selected from optionally substituted C1-4 alkyl or optionally substituted aryl; L is a leaving group selected from diazo, halo, -OSO2R", -OCOR" or -O-Si(R")3; and R" is selected from optionally substituted C1-4 alkyl or optionally substituted aryl.

THIAZOLE DERIVATIVES AS KINASE INHIBITORS

A series of thiazole derivatives which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA

This invention relates to novel compounds which up-regulate LDL receptor (LDL-r) expression and to processes for their preparation, pharmaceutical compositions containing them and their medical use. More particularly, this invention relates to novel aromatic piperidines of formula (I) and their use in therapy.